ABT SEC Filing News — Abbott Laboratories

Latest SEC filings for Abbott Laboratories (ABT) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-02.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement ther…
Sector: Healthcare Industry: Medical Devices Market Cap: $173.3B CIK: 1800
20
Total Filings
0
Bullish Classifications
4
Bearish Classifications
14
Insider Transactions
2
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for ABT currently lean bearish. Of the 20 filing records displayed, 4 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
ABT Filing Activity Snapshot 2026-07-01 — 2026-10-02
Insider Transactions (Form 4)
0 buys vs 3 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$46.20M
Ford Robert B (Director, CHAIRMAN AND CEO) · 2026-08-27
398,832 shares · Form 4
Form 144 Notices
3
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 14 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 14 filings in this group are Form 4s for Abbott Laboratories.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 14 insider filings shown, the breakdown is 9 compensation award, 3 open-market sale and 2 tax withholding. 3 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×9
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×3
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Tax withholding ×2
Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.
Form 4 Compensation award Tax / Compensation Filing 2026-10-02

ABT insider Form 4 filed for equity award, exercise, or tax withholding

Stratton John G (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Equivalent Units 397 $98.83 $39.2K
Filing: Form 4 (Insider Transaction) Insider: Stratton John G (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-10-02

ABT insider Form 4 filed for equity award, exercise, or tax withholding

Gonzalez Patricia Paola (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Equivalent Units 333 $98.83 $32.9K
Filing: Form 4 (Insider Transaction) Insider: Gonzalez Patricia Paola (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-10-02

ABT insider Form 4 filed for equity award, exercise, or tax withholding

Conroy Kevin T (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Equivalent Units 318 $98.83 $31.4K
Filing: Form 4 (Insider Transaction) Insider: Conroy Kevin T (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-10-02

ABT insider Form 4 filed for equity award, exercise, or tax withholding

Ahuja Nita (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Equivalent Units 318 $98.83 $31.4K
Filing: Form 4 (Insider Transaction) Insider: Ahuja Nita (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-10-02

ABT insider Form 4 filed for equity award, exercise, or tax withholding

Roman Michael F (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Equivalent Units 381 $98.83 $37.7K
Filing: Form 4 (Insider Transaction) Insider: Roman Michael F (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-09-25

ABT insider Form 4 filed for equity award, exercise, or tax withholding

Conroy Kevin T (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 52,507 $103.99 $5.46M
Filing: Form 4 (Insider Transaction) Insider: Conroy Kevin T (Director) Shares: 52,507
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-03

ABT insider MCCOY JOHN A. JR. (VICE PRESIDENT AND CONTROLLER) sold 27 shares (~$3.0K)

MCCOY JOHN A. JR., listed as VICE PRESIDENT AND CONTROLLER at ABBOTT LABORATORIES, reported an open-market sale of 27 ABT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 52 $110.36 $5.7K
S Open-market sale 27 $109.54 $3.0K
Filing: Form 4 (Insider Transaction) Insider: MCCOY JOHN A. JR. (VICE PRESIDENT AND CONTROLLER) Shares: 27 Est. Value: $3.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-09-03

ABT insider Form 4 filed for equity award, exercise, or tax withholding

Boudreau Philip P (EVP AND CFO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 388 $110.36 $42.8K
Filing: Form 4 (Insider Transaction) Insider: Boudreau Philip P (EVP AND CFO) Shares: 388
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-27

ABT insider Ford Robert B (Director, CHAIRMAN AND CEO) sold 398,832 shares (~$46.20M)

Ford Robert B, listed as Director, CHAIRMAN AND CEO at ABBOTT LABORATORIES, reported an open-market sale of 398,832 ABT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 151,869 $44.40 $6.74M
M Option exercise 246,963 $59.94 $14.80M
S Open-market sale 218,535 $115.57 $25.26M
S Open-market sale 180,297 $116.19 $20.95M
M Option exercise derivative · Option (right to buy) 151,869 — —
M Option exercise derivative · Option (right to buy) 246,963 — —
Filing: Form 4 (Insider Transaction) Insider: Ford Robert B (Director, CHAIRMAN AND CEO) Shares: 398,832 Est. Value: $46.20M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-13

ABT insider Morrone Louis H. (EXECUTIVE VICE PRESIDENT) sold 5,850 shares (~$642.5K)

Morrone Louis H., listed as EXECUTIVE VICE PRESIDENT at ABBOTT LABORATORIES, reported an open-market sale of 5,850 ABT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 5,850 $109.83 $642.5K
I Discretionary transaction 12 $107.99 $1.3K
Filing: Form 4 (Insider Transaction) Insider: Morrone Louis H. (EXECUTIVE VICE PRESIDENT) Shares: 5,850 Est. Value: $642.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-01

ABT insider Form 4 filed for equity award, exercise, or tax withholding

Stratton John G (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Equivalent Units 432 $90.74 $39.2K
Filing: Form 4 (Insider Transaction) Insider: Stratton John G (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-01

ABT insider Form 4 filed for equity award, exercise, or tax withholding

Roman Michael F (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Equivalent Units 416 $90.74 $37.7K
Filing: Form 4 (Insider Transaction) Insider: Roman Michael F (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-01

ABT insider Form 4 filed for equity award, exercise, or tax withholding

Gonzalez Patricia Paola (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Equivalent Units 363 $90.74 $32.9K
Filing: Form 4 (Insider Transaction) Insider: Gonzalez Patricia Paola (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-01

ABT insider Form 4 filed for equity award, exercise, or tax withholding

Conroy Kevin T (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Equivalent Units 231 $90.74 $21.0K
Filing: Form 4 (Insider Transaction) Insider: Conroy Kevin T (Director)
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Abbott Laboratories has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-02

ABT Form 144 filed for proposed insider sale by John A. McCoy, Jr. (27 shares) ~$3.0K

John A. McCoy, Jr. filed a Form 144 with the SEC indicating intent to sell ABT (ABBOTT LABORATORIES) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: John A. McCoy, Jr. Shares: 27 Est. Value: $3.0K
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-08-25

ABT Form 144 filed for proposed insider sale by Robert B. Ford (398,832 shares) ~$46.20M

Robert B. Ford filed a Form 144 with the SEC indicating intent to sell ABT (ABBOTT LABORATORIES) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Robert B. Ford Shares: 398,832 Est. Value: $46.20M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-11

ABT Form 144 filed for proposed insider sale by Louis H. Morrone (5,850 shares) ~$642.5K

Louis H. Morrone filed a Form 144 with the SEC indicating intent to sell ABT (ABBOTT LABORATORIES) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Louis H. Morrone Shares: 5,850 Est. Value: $642.5K
View on SEC EDGAR → Open Filing Document →
Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Abbott Laboratories. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-20

ABT filed 8-K — material company event

ABBOTT LABORATORIES filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-16

ABT filed 8-K — material company event

ABBOTT LABORATORIES filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Abbott Laboratories.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-07-28

ABT filed Quarterly Report (10-Q)

ABBOTT LABORATORIES filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Abbott Laboratories's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on ABT. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — ABT SEC Filings

What SEC filings does Abbott Laboratories submit to the SEC?

Abbott Laboratories (ABT) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about ABT?

A Form 4 for ABT discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Abbott Laboratories?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for ABT?

The 10-K is Abbott Laboratories's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all ABT SEC filings directly on EDGAR?

You can view all historical Abbott Laboratories filings on the SEC EDGAR company page for ABT. Each filing card on this page links directly to the original SEC document.

How often does Abbott Laboratories file with the SEC?

Abbott Laboratories files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling ABT shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

More Tools for ABT

ABT Full Stock Analysis ABT Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper ABT analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the ABT stock analysis page.

ABT Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer